Cardiac manifestations of acute carbamate and organophosphate poisoning

A M Saadeh, N A Farsakh, M K Al-Ali

Abstract

Objective—To study the frequency, extent, and pathogenesis of the cardiac complications accompanying organophosphate and carbamate poisoning.

Design—Retrospective study.

Setting—A medical intensive care unit (MICU) of a general hospital.

Subjects—46 adult patients admitted over a five year period with a diagnosis of organophosphate or carbamate poisoning.

Results—Cardiac complications developed in 31 patients (67%). These were: non-cardiogenic pulmonary oedema, 20 (43%); cardiac arrhythmias, 11 (24%); electrocardiographic abnormalities including prolonged Q-Tc interval, 31 (67%); ST-T changes, 19 (41%); and conduction defects, 4 (9%). Sinus tachycardia occurred in 16 patients (35%) and sinus bradycardia in 13 (28%). Hypertension developed in 10 patients (22%) and hypotension in eight (17%). Eight patients (17%) needed respiratory support because of respiratory depression. Although more than two thirds of the patients (67%) had a prolonged Q-Tc interval, none had polymorphic ventricular tachycardia of the torsade de pointes type. Two patients died from ventricular fibrillation, an in hospital mortality of 4%.

Conclusions—Cardiac complications often accompany poisoning with these compounds, which may be serious and often fatal. These complications are potentially preventable if they are recognised early and treated adequately. The extent, frequency, and pathogenesis of the cardiac toxicity from these compounds has not been clearly defined.

The current body of knowledge largely consists of limited studies and case reports. Therefore many physicians may not be fully aware of the complications. In this study we report our experience with 46 adult patients after acute intoxication with these compounds.

Methods

Over a five year period (January 1990 to January 1995) 47 patients with organophosphate or carbamate poisoning were admitted to the medical intensive care unit (MICU) of Princess Basma Teaching Hospital, North Jordan. Only 46 were included in the study. One case was excluded because of a past cardiac history. Patients were admitted to the MICU either directly from the emergency department or as later transfers from general medical wards.

Resources for estimation of blood cholinesterase activity were not available. Therefore, the diagnosis of organophosphate or carbamate poisoning depended upon: (1) a history or evidence of exposure to organophosphate compounds or carbamates within the previous 24 hours; (2) characteristic manifestations of organophosphate and carbamate poisoning, including miosis, fasciculations, and excessive salivation; and (3) improvement of the signs and symptoms of organophosphate and carbamate poisoning after administration of high doses of atropine. All these criteria were required to be present in each patient to be included in the study.

Data on the age, sex, type and source of the poisonous agent, need for assisted ventilation, duration of hospital stay, and the in-hospital outcome were obtained from the case notes. Electrocardiograms were carried out twice daily on all patients during their stay in the MICU. Chest x ray and estimation of serum electrolytes and cardiac enzymes (creatine kinase (CK) and lactate dehydrogenase (LDH)) were routinely done on admission to the MICU. Cardiac enzyme estimations were repeated on the following two days. Blood pressure, pulse rate, and ECG recordings taken on arrival in the emergency department or in the general medical wards were selected for analysis before the start of atropine treat-
Table 1  Age and sex distribution

<table>
<thead>
<tr>
<th>Age groups (years)</th>
<th>Female</th>
<th>Male</th>
<th>Total (%)</th>
<th>F:M ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>15–19</td>
<td>11</td>
<td>7</td>
<td>18 (39)</td>
<td>1:6:1</td>
</tr>
<tr>
<td>20–24</td>
<td>15</td>
<td>8</td>
<td>23 (46)</td>
<td>2:1</td>
</tr>
<tr>
<td>25–29</td>
<td>4</td>
<td>5</td>
<td>9 (20)</td>
<td>0:8:1</td>
</tr>
<tr>
<td>30 and over</td>
<td>1</td>
<td>6</td>
<td>7 (15)</td>
<td>0:1:7:1</td>
</tr>
<tr>
<td>Total</td>
<td>24</td>
<td>22</td>
<td>46 (100)</td>
<td>1:1:1</td>
</tr>
</tbody>
</table>

Table 2  Type of poisonous agent

<table>
<thead>
<tr>
<th>Type</th>
<th>Females</th>
<th>Males</th>
<th>Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamyl carbamate</td>
<td>13</td>
<td>7</td>
<td>20</td>
</tr>
<tr>
<td>Carbaryl carbamate</td>
<td>4</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Bendiocarb carbamate</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>19</td>
<td>13</td>
<td>32 (70)</td>
</tr>
<tr>
<td>Organophosphates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dichlorvos</td>
<td>2</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Quaihalphos</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Diazion</td>
<td>—</td>
<td>2</td>
<td>—</td>
</tr>
<tr>
<td>Dimethoate</td>
<td>—</td>
<td>2</td>
<td>—</td>
</tr>
<tr>
<td>Total</td>
<td>3</td>
<td>9</td>
<td>12 (26)</td>
</tr>
</tbody>
</table>

*The type of poisonous agent was unidentified in two females (4%).

ECG analysis included the rate, rhythm, ST/T abnormalities, conduction defects, and measurement of P-R and Q-T intervals. The Q-T interval was corrected (Q-Tc) according to the formula of Bazett.

Data are expressed as mean (SD). The Student t test was used to determine significance. Results with P < 0:05 were considered statistically significant.

Results
Forty-six case records (24 females and 22 males) were reviewed. The mean age was 23.95 (9.2) years. There was no significant difference in the mean age between males, 26 (10) years, and females, 22 (8) years (P = 0.07). Table 1 gives the age and sex distribution patterns of the patients and table 2 shows the type of poisonous agents.

The major cause of poisoning was suicidal intention (67%), followed by accidental ingestion (24%); only 9% were due to occupational exposure. Electrocardiographic and other cardiac manifestations are presented in table 3. This table refers only to the manifestations recorded before the administration of atropine. Thirty-one patients (13 males and 18 females) had a prolonged Q-Tc interval (≥ 0.47 s) with no significant difference between the males (0.48–0.08 s) and females (0.47–0.03 s) (P = 0.23). Prolongation of the Q-Tc interval (≥ 0.42 s in males and ≥ 0.43 s in females) was the most common ECG abnormality (67%), followed by sinus tachycardia (35%). Elevation of the ST segment (> 2 mm above the isoelectric line) was seen in 11 cases (24%). This was most striking (> 3 mm) in the anterior precordial leads (V2–V4). The ST segment remained elevated for two days in seven cases, three days in three cases, and five days in one case. Of these 11 cases, five were associated with raised cardiac enzymes (mean values, 516 and 782 IU/l for CK and LDH, respectively).

T wave inversion was seen in eight cases (17%) and involved the anterior leads (I, aVL, V1–V5) in three cases, the inferior (II, III, aVF) in three, and the inferolateral (II, III, aVF, V5, V6) in two. Of these, only one case had a mild increase in cardiac enzymes (328 and 520 IU/l for CK and LDH, respectively).

First degree heart block (P-R interval ≥ 0.22 s) occurred in four cases (9%). No other conduction defect was observed. Atrial fibrillation was seen in four patients, all males, and was present at the time of admission before the start of atropine treatment. Of these, three cases had acute pulmonary oedema and severe hypoxaemia, and one had ST elevation in the anterior precordial leads (V2–V4) with raised cardiac enzymes.

Ventricular premature contractions were seen in three cases (6%) and ventricular tachycardia in four (9%). Interestingly, none of these four patients had polymorphic ventricular tachycardia of the torsade de pointes type. Of these four cases, two had short runs which subsided after short doses of intravenous lignocaine and the other two degenerated into ventricular fibrillation leading to death despite repeated doses of lignocaine and other resuscitative measures. Both cases were males with organophosphate poisoning. Neither of these two had a prolonged Q-Tc interval.

Non-cardiogenic pulmonary oedema, shown on chest x ray as fluffy infiltrates in the periphery of both lung fields with normal heart size, occurred in 20 patients (43%). The clinical and radiological signs resolved completely in 19 patients within 24 hours with atropine treatment alone. One case required repeated doses of intravenous furosemide for 48 hours. Of these 20 patients, eight (17%) required respiratory support because of respiratory depression. Hypertension (systolic arterial pressure ≥ 160 mm Hg and/or diastolic pressure ≥ 90 mm Hg) was observed in 10 (22%), and hypotension (systolic arterial pressure ≤ 90 mm Hg) occurred in eight cases (17%). The electrocardiographic and other cardiac abnormalities all returned to normal before the patients were discharged.

Discussion
The mechanism by which organophosphates and carbamates induce cardiotoxicity is still uncertain. Ludomirsky et al5 described three phases of cardiac toxicity after organophosphate poisoning: phase 1, a brief period of increased sympathetic tone; phase 2, a pro-
Cardiac manifestations of acute carbamate and organophosphate poisoning

A prolonged period of parasympathetic activity; and phase 3, in which Q-T prolongation followed by torsade de pointes ventricular tachycardia and then ventricular fibrillation occur.

Both sympathetic and parasympathetic overactivity have been shown to cause myocardial damage.8-10 As early as 1974, Yasue et al11 postulated that parasympathetic overactivity plays a major role in coronary artery spasm, and later Horio et al12 induced coronary artery spasm in adult humans with healthy coronary arteries after intracoronary injection of acetylcholine. In a series of 168 cases of organophosphate poisoning reported by Kiss and Fazekas,4 five had a transient picture of myocardial infarction. Diffuse myocardial damage was found at necropsy in two cases of malathion poisoning (an old generation organophosphate)13 and diffuse myocarditis has been reported after carbamate poisoning.5

In our series the majority of patients with arrhythmia (three with atrial fibrillation and two with ventricular tachycardia) had severe anoxia and pulmonary oedema on admission during the early cholinergic phase of the poisoning. Two of the four patients with atrial fibrillation had hypokalaemia and one had transient elevation of the ST segment and raised cardiac enzymes. Of the 11 patients with ST segment elevation, five had raised cardiac enzymes. These findings and the above studies suggest that the cardiac toxicity associated with organophosphate and carbamate poisoning is caused by more than one mechanism. Possible mechanisms include sympathetic and parasympathetic overactivity, hypoxaemia, acidosis, electrolyte derangements, and a direct toxic effect of the compounds on the myocardium.

Some investigators14 have described a polymorphic ventricular tachycardia of the torsade de pointes type attributed to a prolongation of the Q-Tc interval associated with organophosphate poisoning. In spite of the presence of a prolonged Q-Tc interval in the majority of our patients (67%), none of them had this type of arrhythmia. Hassler et al15 studied the effect of an intravenous organophosphate compound (Soman) on the electrical properties of foxtound hearts. Although significant ventricular ectopic activity, idioventricular rhythm, and recurrent bouts of ventricular tachycardia occurred, torsade de pointes ventricular tachycardia was not observed.

Administration of atropine in high doses has been implicated in the development of ventricular arrhythmias.4,15-16 In our study there was no such correlation. Lyzhnikov et al17 and Ludomisky et al18 also found no correlation between atropine therapy and ventricular arrhythmias in organophosphate poisoning.

Hypertension and sinus tachycardia, which may be seen in organophosphate and carbamate poisoning, are nicotinic effects, while hypotension and sinus bradycardia are cholinergic manifestations.19 Although bradycardia is thought to dominate in the early cholinergic phase of the poisoning, sinus tachycardia was a more frequent finding in our study. The same observation has also been made by others.19,20 Some investigators consider the presence of hypertension and sinus tachycardia to be manifestations of severe poisoning.20

Hypertension was seen in 22% and sinus tachycardia in 35% in our study. Of these cases, only 21% can be considered to have had severe poisoning as indicated by death (4%) or the need for assisted ventilation (17%). Ninety six per cent (44/46) of the patients recovered fully and only 4% (two cases) died. No chronic sequelae were noted. We believe that the type of poisonous agent (organophosphate versus carbamates), the severity of the poisoning, the stage at which treatment is started, and the presence or absence of MICU facilities are the main determinants for the hospital mortality.

In conclusion, cardiac complications associated with organophosphate and carbamate poisoning are not fully appreciated by many physicians. Most occur during the first few hours after exposure. Hypoxaemia, acidosis, and electrolyte derangements are major predisposing factors for the development of these complications. Once this condition is recognised, the patient should immediately be transferred to an intensive or coronary care unit where appropriate monitoring and resuscitative facilities are available. Intensive supportive treatment, meticulous respiratory care, and administration of atropine in adequate doses very early in the course of the illness are the keys to successful management of these cases.

We thank Dr David Todd for help with the manuscript and Mrs L. Haddad for typing the manuscript.

Cardiac manifestations of acute carbamate and organophosphate poisoning.

A. M. Saadeh, N. A. Farsakh and M. K. al-Ali

Heart 1997 77: 461-464
doi: 10.1136/hrt.77.5.461